Johnson & Johnson (NYSE:JNJ) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 20, 2016
Zacks Investment Research has downgraded Johnson & Johnson(NYSE:JNJ) to Hold in a report released on Tuesday September 20 2016.
On 9/13/2016, Zacks Investment Research released a statement about Johnson & Johnson(NYSE:JNJ) raised the target price from $0.00 to $133.00. At the time, this suggested an upside of 0.12%.
Displaying a price of $117.66, Johnson & Johnson (NYSE:JNJ) traded 0.37% higher on the day. With the last stock price close up 1.76% from the two hundred day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same time period. Johnson & Johnson has recorded a 50-day moving average of $120.64 and 200-day moving average of $116.04. Trade volume was was down over the average, with 3,202,067 shares of JNJ changing hands under the typical 6,675,420 shares.
Recent Performance Graph:
Johnson & Johnson has a one-year low of $89.90 and a one-year high of $126.07 with a PE ratio of 22 and has a market capitalization of $0.0.
In addition to Zacks Investment Research reporting its price target, a total of 18 firms have released a research note on the company. The one year target price is $117.44 with 0 rating the stock a strong buy, 0 rating the company a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and finally 0 firmsrating the stock as sell.
General Information About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, and Switzerland and the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.